Tesaro Inc (NASDAQ:TSRO) Sees Fall in Stock Price - Down $0.39

Lester Mason
November 15, 2017

The company's revenue was up 740.3% on a year-over-year basis. sell-side analysts forecast that TESARO will post -8.18 earnings per share for the current fiscal year. The Firm has five divisions, which include Products, Subscription, Professional services, Training and Maintenance.

TESARO (NASDAQ TSRO) opened at $91.09 on Thursday. Therefore 50% are positive.

TESARO, Inc. has a twelve month low of $89.00 and a twelve month high of $192.94. Numis Securities maintained it with "Buy" rating and GBX 76 target in Monday, February 1 report.

Several other equities research analysts have also recently commented on TSRO. reaffirmed a "neutral" rating and set a $140.00 target price (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Oppenheimer maintained TESARO Inc (NASDAQ:TSRO) on Tuesday, August 8 with "Buy" rating. The stock of TESARO Inc (NASDAQ:TSRO) has "Outperform" rating given on Monday, August 24 by Leerink Swann. The company was initiated on Thursday, March 17 by Citigroup. Wedbush maintained TESARO Inc (NASDAQ:TSRO) rating on Wednesday, March 15. The stock has "Outperform" rating by FBR Capital on Tuesday, December 27. The firm has "Outperform" rating given on Friday, August 18 by Credit Suisse. Three months ago, analysts assigned TSRO a 4.20 rating, which implies that analysts have become more pessimistic about the outlook for the stock over the next year. Fiera holds 131,924 shares or 0.09% of its portfolio.

Guggenheim Capital LLC now owns 94,494 shares of the biopharmaceutical company's stock valued at $7,942,000 after buying an additional 9,354 shares in the last quarter. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The Firm operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. The share price was last seen 3.45% higher, reaching at $41.34 on November 13, 2017. TESARO Inc (NASDAQ:TSRO) has risen 254.28% since November 13, 2016 and is uptrending. It has outperformed by 237.58% the S&P500.


Investors sentiment increased to 1.46 in 2017 Q2. Greenwood Assoc Lc has 0.07% invested in TESARO Inc (NASDAQ:TSRO) for 1,895 shares. It is positive, as 38 investors sold TESARO Inc shares while 70 reduced holdings. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company's stock valued at $504,230,000 after buying an additional 195,590 shares during the last quarter. That brings the Sr VP's holdings to $753,229 as reported to the SEC. Millennium Mngmt Ltd invested in 0.08% or 323,268 shares. Blue Bell Private Wealth Mgmt Ltd invested in 0.01% or 1,670 shares. Great West Life Assurance Com Can owns 9,620 shares. State Street holds 1.17M shares or 0.01% of its portfolio. Old Mutual Customised Solutions (Proprietary) Limited accumulated 700 shares. Moreover, Hillhouse Mngmt has 0.06% invested in TESARO Inc (NASDAQ:TSRO) for 29,697 shares. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & worldwide copyright & trademark laws. Gam Ag accumulated 0.03% or 16,086 shares. Us Bank & Trust De reported 0% of its portfolio in PCF Group PLC (LON:PCF).

Since June 6, 2017, it had 0 insider buys, and 1 insider sale for $1.18 million activity. The average investment rating for TSRO on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 3.88 or a Hold. SunTrust Banks, Inc. reiterated a "buy" rating and set a $160.00 price target on shares of TESARO in a research note on Friday. Analysts anticipate that traders could see stock price minimum in the $30 range (lowest target price). The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. GUID was included in 5 notes of analysts from November 11, 2016. The stock has "Outperform" rating by Imperial Capital on Friday, November 11. The firm has "Buy" rating by Lake Street given on Monday, November 7. The stock of Guidance Software, Inc. (NASDAQ:GUID) has "Buy" rating given on Tuesday, February 14 by Benchmark. (NASDAQ:GUID) rating on Monday, April 10. Wedbush has "Outperform" rating and $164 target. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company's stock worth $206,000 after acquiring an additional 1,430 shares during the period. They now have a $143.00 price target on the biopharmaceutical company's stock. The Connecticut-based Bourgeon Capital Management Llc has invested 0.43% in the stock. Iguana Healthcare Management Ltd Liability Corp, a New York-based fund reported 15,000 shares.

It closed at $7.07 lastly. It has underperformed by 8.11% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER